Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction

Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedure

2. Male or female, aged ≥ 19 years

3. Patients with chronic HF (Chronic Heart Failure) NYHA (New York Heart Associationclassification) class II-IV and preserved EF (Ejection Fraction)(LVEF (LeftVentricular Ejection Fraction) > 40 %) and elevated NT-proBNP (N-terminal of theprohormone brain natriuretic peptide) > 200 pg/ml for patients without AF, OR > 600pg/ml for patients with AF, analysed at the Central laboratory at Visit 1

4. Structural heart disease within 6 months prior to Visit 1 using echocardiagraphy

Exclusion Criteria:

1. Myocardial infarction, coronary artery bypass graft surgery or other majorcardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 daysprior to Visit 1

2. Contraindication to beta blocker

3. Heart transplant recipient or listed for heart transplant

4. Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiacinvasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)

5. Acute decompensated HF (Heart Failure)

6. Symptomatic hypotension or systolic blood pressure < 100 mmHg)

7. Patients with CrCl < 30 ml/min using creatinine-based CKD-EPI equations

8. Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis

9. Symptomatic bradycardia or heart rate < 60/min

10. Allergy, adverse drug reaction, hypersensitivity to carvedilol

11. Life expectancy < 6 months (e.g. metastatic malignancy)

12. Pregnancy, or women of childbearing age